BioXcel Therapeutics Preps IGALMI At-Home Launch Ahead of Nov. 14 FDA Label Decision

BioXcel Therapeutics (NASDAQ: BTAI) outlined its commercial strategy and launch preparations for IGALMI as it awaits a U.S. Food and Drug Administration decision on an expanded label for at-home treatment of acute agitation episodes associated with bipolar disorder and schizophrenia. The company is working toward a November 14 PDUFA target action date for its supplemental new